cyrilzakka/clinical-trials huggingface dataset:
Histological Differentiation Grade Predicted by Ultrasound Backscatterer Imaging

Histological grade of hepatocellular carcinoma (HCC) is an important prognostic factor affecting patient survival. It has been divided into four grades from I to IV on the basis of histological differentiation. Grade I is the best differentiated consisting of small tumor cells arranged in thin trabeculae. Cells with higher grade are larger and less differentiated with hyperchromatic nuclei and loss of trabecular pattern.

Ultrasound is an imaging modality frequently used to evaluate liver tumors because of its convenience, real-time, less expensive and no radiation exposure. However, ultrasonographic evaluation by conventional B-mode image is semi quantitative and subjective. It still cannot replace liver biopsy for the evaluation of HCC.

This study is aimed to quantify the image characters of B-mode image and the scatterer properties using Nakagami distribution. Nakagami parameter is a general model to describe the distribution of scatterers. Therefore, the investigators hypothesized that Nakagami parameter may also reflect the histological changes in different grades of HCC.

In this study, the resected HCC tumor samples will be collected from the participants who are going to receive surgical resection, and the tumor US images and Nakagami values will be obtained via the single-element ultrasound system. The correlation between the ultrasound backscatter parameter and the differentiation grade will be analyzed.


Eligibility Criteria:
Inclusion Criteria:

* Age 21 to 75
* Patients with HCC who underwent surgery
* The resected tumor was measured larger than 3 cm

Exclusion Criteria:

* Patients who have received other treatment in 6 months
* Patients who couldn't regular follow-up
Assessment of Stress and Anxiety for Patients Undergoing MRI Using, Holy Quran, Music, and Natural Sounds

The aim of the current study is to analyze the effect of listening to Quran or music or natural sounds on anxiety and stress level among patients undergoing MRI.

After informed consents will be obtained from patients undergoing Magnetic Resonance Image (MRI). A randomized Controlled Parallel design will be used to assess the effectiveness of listening to Quran, music, and natural sound to reduce anxiety and stress level among patients undergoing MRI in Palestine. A control group will receive the traditional care during MRI without listening to any sound, while the intervention groups will listen to either Quran, music, or natural sounds during the MRI scan. Notice that each patient will choose the preferred method to be in one of the four mentioned groups. This study will include participants with predetermined specific eligibility criteria.

Eligibility Criteria:
Inclusion Criteria:

* Who agreed to participate in this study.
* Both sex.
* Age of 18 years and above.
* Fully conscious and oriented.

Exclusion Criteria:

* Referrals from the intensive care unit.
* Life-threatening situations.
* General ill health,
* Serious psychological disorders.
* Invasive MR imaging procedures (such as biopsies).
* Being under the age of 18, and
* Exams that were particularly scheduled for other investigations.
Clinical Research Study to Learn About the Effect and Safety of Different Doses of FE 999302 When Given as a Single Dose for Final Development of the Eggs After Ovarian Stimulation

The primary purpose of this trial is to compare three different doses of FE 999302 with 250 µg OVITRELLE and 10,000 IU NOVAREL on oocyte maturity when administered as a single dose for final development of the oocytes in women undergoing controlled ovarian stimulation.


Eligibility Criteria:
Inclusion Criteria:

* Pre-menopausal women between the ages of 18 and 42 years. The subjects must be at least 18 years (including the 18th birthday) and no more than 42 years (up to the day before the 43rd birthday) when they sign the informed consent.
* Infertile women diagnosed with tubal infertility, unexplained infertility, endometriosis stage I/II or with partners diagnosed with male factor infertility, eligible for in vitro fertilisation (IVF) and/or intracytoplasmic sperm injection (ICSI) using fresh or frozen ejaculated sperm from male partner or sperm donor.
* Infertility for at least 1 year before screening for subjects \<35 years or for at least 6 months for subjects ≥35 years (not applicable in case of tubal or severe male factor infertility).
* No more than two controlled ovarian stimulation cycles initiated, regardless outcome (taking exclusion criteria 3, 4, and 5 into account).
* Regular menstrual cycles of 24-35 days (both inclusive), presumed to be ovulatory.

Exclusion Criteria:

* Known polycystic ovary syndrome (PCOS) associated with anovulation or known endometriosis stage III-IV (American Society for Reproductive Medicine, 2012).
* Considered unsuitable for controlled ovarian stimulation with a starting dose of 150 or 225 IU/day highly purified human menopausal gonadotropin (HP-hMG), as judged by the investigator.
* Poor response in a previous controlled ovarian stimulation cycle using a gonadotropin starting dose of 150 IU/day or higher. Poor response is defined as \<4 oocytes retrieved, or cycle cancellation prior to oocyte retrieval due to inadequate follicular development.
* Excessive ovarian response in a previous controlled ovarian stimulation cycle for IVF/ICSI using a daily FSH/hMG dose of ≤225 IU, defined as ≥25 oocytes retrieved or cycle cancellation prior to oocyte retrieval due to excessive ovarian response, including risk of ovarian hyperstimulation syndrome (OHSS).
* Severe OHSS in a previous controlled ovarian stimulation cycle.
Effects of Low Intensity Blood Flow Restriction on Clinical Outcomes in Women With Knee Osteoarthritis

Objective is to compare the effects of routine physical therapy with and without low intensity blood flow restriction on pain and quadriceps muscle strength in women with knee osteoarthritis.

A single blinded randomized controlled trial conducted at Department of Physiotherapy, University of Lahore Teaching Hospital, Defense Road, Lahore.

Total 60 participants were randomly assigned in to two groups, with 30 in each group The intervention group received routine physiotherapy program combined with Low Intensity Blood Flow Restriction Technique (LI-BFR. While control group were treated with only routine physiotherapy.

Dynamometer was used to assess the knee extensor strength while Knee injury and osteoarthritis outcome score was used to record any exacerbation in pain and effects of BFR on activities of daily living. Training load determined 20% of 1RM. Data analysis had done on SPSS version 23.

nonparametric test Friedman test was for comparison within the groups and Mann Whitney U test was used for comparison between groups.

Randomization had done through the sealed envelope method. After allocation subjects had received their treatment protocals.

Eligibility Criteria:
Inclusion Criteria:

* Diagnosed patients of grade II knee osteoarthritis
* Patient's age 45-65

Exclusion Criteria:

* Bilateral knee replacement
* Lower limb surgery in the last six months
* Diagnosis of inflammatory joint or muscle disease
* Chest pain during exercise or at rest; or need for supplemental oxygen
* Pregnancy
* Any systemic disease
Effect of Laser Acupuncture Alone or Combined With Pranayama Exercise on Inflammation in Allergic Rhinitis

Allergic rhinitis (AR) represents one of the most common global health problems with seriously increasing incidence over the last decades.The goal of the treatment of rhinitis is to prevent or reduce the symptoms through reduction of the inflammation of affected tissues. Acupuncture and pranayama yoga exercises had reported a significant improvement in daily symptoms and an increase of symptom-free days in many studies enrolling patients.

Sixty Egyptian children with allergic rhinitis, after randomization, will be divided to 2 groups; the first 30-children group will receive 2-session per-week laser stimulation for 6 weeks to some selected acupoints and daily pranyama exercises (nearly every session will be one hour, for six weeks), the second group will receive 2-session per-week laser stimulation for six weeks to some bilateral selected acupoints. the stimulated points will be (LI 19, LI 20, ST2, and ST4. ST6, ST7, ST17, ST36, SI18, BL2, GB14, GV24 and EXHN5). Every acupoint will be stimulated with laser power of 100 mw that will be used on a spot area of 1 cm2 for 1 minute.

Eligibility Criteria:
Inclusion Criteria:

* allergic rhinitis children
* physician-based diagnosis of allergic rhinitis

Exclusion Criteria:

* children with intellectual disabilities
* chest disease or heart disease or local congenital nose deformities
* participants received within-previous-six-months self-prescribed or by-therapist prescribed complementary therapies
Evaluation of the Fortilink IBF System With TETRAfuse Technology

This is a multi-center, post-market, retrospective study to collect safety and performance data for patients implanted with the Fortilink IBF System.

This is a multi-center, post-market, retrospective study to collect safety and performance data for patients implanted with the Fortilink IBF System.

The study will include up to 110 patients at up to 8 US sites. All patients implanted with the Fortilink System at a site will be included in the data collection. The goal is to collect data for at least 100 subjects, but the sample size will be capped at 110 to ensure that all patients at a given site are included in the analysis.

Eligibility Criteria:
Inclusion Criteria:

* Patient must have had an attempted implant of the Fortilink IBF System

Exclusion Criteria:

* There are no exclusion criteria
A 3D Tablet Sensor Approach to the Measurement of a Lymphedema

Up to now, the diagnosis of lymphedema remains hard and delayed. It suffers from many limitations such as lack of coordination and formation of the health-care network. The diversity of used tools is another obstacle because all provided solutions on the market are either costless with poor accuracy, or highly expensive but with excellent accuracy. Therefore, we decided to evaluate an affordable and open-source 3D iPad sensor sharing the same technology used in Kinect sensors.


Eligibility Criteria:
Inclusion Criteria:

- Unilateral lymphedema

Exclusion Criteria:

* Minor patient,
* Bilateral lymphedema,
* Trophic disorders: Acute or recent skin infection (\<1 month after the end of antibiotic therapy), unhealed wounds.
* Predictable difficulties in carrying out the measurements due to the patient's physical limitations (maintenance of orthostatic or sitting position \<5 minutes)
* Single or bilateral edema with a different etiology than lymphedema.
Transition From Adolescents to Adulthood for Patients With Congenital Heart Diseases

The Investigators aim to measure the impact of a transition program in congenital cardiology in terms of health-related quality of life.

The number of adults with congenital heart diseases (CHD) is increasing. However, many young adults are lost to follow-up even in experienced tertiary care centers. American and European guidelines recommend to improve the management of young adults with CHD. Structured therapeutic education programs are therefore needed to optimize the transfer to adult healthcare. Our tertiary care CHD center recently implemented a transition program and simultaneously investigators decided to measure its impact. Indeed investigators need data from randomized trials in this filed. After previous controlled quality of life studies among children and adults with CHD, investigators chose to use the health-related quality of life (HR-QoL) as primary endpoint in this randomized study to focus on patient related outcomes.

The investigators assume that patients who participate in this program will improve their quality of life compared to controls. If investigators demonstrate the benefit of this program, it will have important consequences for patients with CHD and eventually for patients with other chronic medical conditions.

Eligibility Criteria:
Inclusion Criteria:

* Patient from 13 years to 25 years inclusive.
* Carrying of Congenital Heart Disease as defined in the International Classification.
* Possible follow-up for one year on one of the three hospital center.
* Informed consent of the patient for adults and, parents or legal guardians for minors.
* Affiliation to a social security system.

Exclusion Criteria:

* Non-francophone,
* Severe intellectual impairment.
Transcranial Direct Current Electrical Stimulation (tDCS) in Drug-resistant Epilepsy

This project aims to conduct a pilot study based on the targeting of the epileptogenic zone previously localized very precisely by stereoelectroencephalography (SEEG). SEEG is used as part of the pre-surgical assessment. It consists, thanks to the intracerebral implantation of electrodes in the brain of patients, to perform an intracerebral electrophysiological recording and thus to precisely explore the epileptogenic regions.

In order to study the neuromodulatory and therapeutic effects of tDCS on epileptic brains, non-invasive techniques for measuring electrophysiological brain activity such as magnetoencephalography (MEG) and high-resolution electroencephalography (HR EEG) will be used.

Finally, since epilepsy is considered to be a disorder of brain functional networks associated with disturbed brain connectivity, the effects of tDCS on cortical excitability by studying the variations in functional connectivity induced by stimulation will be studied.


Eligibility Criteria:
Inclusion Criteria:

* - Age: Older than 12 years old
* Patients with drug-resistant focal epilepsy with no surgical indication or with a previous surgical failure or refusing surgery.
* SEEG previously performed before inclusion with an adequate definition of the epileptogenic zone
* A clinical or research MRI scan that is suitable for navigated brain stimulation (NBS) and definition of target area.
* Number of seizures \>3/month during the baseline (before the first session of tDCS treatment), for at least 3 months
* Have stable medications for the whole study duration and few weeks before
* Total IQ\>65
* Be able to understand, speak and write in French
* Patient, parents or legally representative who have given written informed consent to allow the study data collection procedures,
* Be a beneficiary of affiliated to a health insurance plan

Exclusion Criteria:

* - Generalized epilepsy
* Presenting contraindication to MRI, a serious intercurrent pathology, a progressive brain tumor
* Skin conditions (e.g., eczema, lesion)
* Any cranial metal implants (excluding \<1 mm thick epicranial titanium skull plates and dental fillings) or medical devices (i.e. cardiac pacemaker, deep brain stimulator, medication infusion pump, cochlear implant).
* Previous surgeries opening the skull leaving skull defects capable of allowing the insertion of a cylinder with a radius greater or equal to 5 mm.
* Metal inside the head (outside the mouth) such as shrapnel, surgical clips
* Patient currently participating in another clinical trial or having participated in a clinical trial in the month prior to inclusion.
* Any condition that makes the study subject, in the opinion of the investigator, unsuitable for the study.
* Person protected by articles L1121-5, L1121-6 and L1121-8 of Public Health Code (pregnant or breastfeeding woman, deprived of liberty by judicial decision, situations of social fragility, adults unable or unable to express their consent).
The Effects of Dis/Reconnection of Implant Abutments on Peri-implant Bone Levels

The aim of this study was to evaluate the effects of definitive abutment connection at the time of implant placement on peri-implant bone levels and soft tissue changes in posterior maxilla and mandible regions.

A total of 38 implants were placed in 17 patients with at least 2 missing posterior teeth in the maxilla or the mandible for this study. Each patient received 2 or 4 implants. A definitive prefabricated abutment (test group) was randomly connected to one implant at implant placement (T0) and left undisturbed throughout the duration of the study. On the other implant, a healing abutment (control group) was connected and subjected to go through three disconnections and reconnections at 3 months (T3), 6 months (T6), and 12 months (T12) after the implant placement. Throughout the study period (1 year), all implants remained unrestored. Marginal bone level changes (MBLC) were assessed using standardized periapical radiographs taken at T0 and T12. Peri-implant soft tissue parameters including the keratinized mucosa width and lingual mucosa thickness were also recorded and evaluated.

Eligibility Criteria:
Inclusion Criteria:

* Minimum age 18
* Good oral hygiene
* Healed site that possess two or more missing teeth in the maxillary or mandibular posterior region (excluding third molars)
* Adequate bone to accommodate at least a 4.3 mm diameter and 8mm length implant at each site
* Have at least 8mm interocclusal restorative space
* Willing to participate and attend the planned follow-up visits.

Exclusion Criteria:

* History of alcohol/drug dependency, or any medical, physical, or psychological factor that might affect the surgical or prosthodontic procedures and follow-up examinations
* History of radiation therapy to the head and neck region
* History or current habit of smoking
* History or current habit of bruxism
* No opposing occluding dentition or prostheses
* Need for bone augmentation during implant placement
* Implant insertion torque value \<35 Ncm
Role of Left Stellate Ganglion Block in Offering Myocardial Protection in On-pump Mitral Valve Replacement? A Histopathological and Clinical Assessment

Can pre-operative left stellate ganglion block offer myocardial protection in on-pump mitral valve replacement? A histopathological and clinical assessment.


Eligibility Criteria:
Inclusion Criteria:

* Adult population of both sex, between 25-50 years, will undergo elective on pump mitral valve replacement

Exclusion Criteria:

* -Combined valve replacement ( mitral and aortic or mitral and tricuspid valves replacement).
* Emergency valve replacement ( stuck valve, infective endocarditis).
* Pre-operative cardiomyopathy (Ejection fraction less than 45%).
* Recent myocardial infarction ( within 6 months)
* Redo mitral valve replacement.
* Pre-operative pacing, or cardioverter, any form arrhythmia ( tachy or brady).
* Previous history of carotid endarterectomy or presence of carotid stent.
* On thrombolytic therapy.
* Severe chronic obstructive airway disease,
* Patient refusal
A Study Evaluating STA-9090 in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor (GIST)

The purpose of this study is to determine if STA-9090 is effective in the treatment of patients with metastatic and/or unresectable GIST.

Planned:

* Stage 1: 23 patients. If ≥4 patients had clinical benefit, an additional 32 patients were to be enrolled. Up to 3 additional patients with platelet-derived growth factor receptor, alpha polypeptide (PDGFRA) mutation were to be enrolled, regardless of the total study enrollment.
* Stage 2: 55 patients. Progressing to this stage was dependent on Stage 1 results.

Analyzed:

* Stage 1: 27 patients were enrolled and analyzed. The study was not expanded to Stage 2 due to insufficient efficacy.

Eligibility Criteria:
Inclusion Criteria:

* Must be at least 18 years of age at the time of study entry
* Must have histologically confirmed metastatic and/or unresectable GIST
* Must have measurable disease on computed tomography or magnetic resonance imaging as defined by Response Evaluation Criteria in Solid Tumors (RECIST)
* Must have documented failure (due to either progression or intolerance)of at least prior imatinib and sunitinib. Previous administration of other known heat shock protein 90 (Hsp90) inhibitors is permitted
* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
* Must have acceptable laboratory values as defined in the protocol

Exclusion Criteria:

* Known central nervous system metastases
* Major surgery within 4 weeks prior to receiving STA-9090
* Use of any investigational agents within 2 weeks or 6 half-lives of the agent, whichever is shorter prior to receiving STA-9090
* No treatment with chronic immunosuppressants
* Must have otherwise adequate health status as defined in the protocol
* Left ventricular ejection fraction (LVEF) \< than or = 50% at baseline
* Baseline corrected QT interval (QTc) \> 470 msec
* Pregnant or lactating females
Changes of Immunologic Function in Patients of Prostate Cancer Induced After Cryoablation.

1. The overall objective of the study: By evaluating the curative effect of CSAP in localized prostate cancer, locally advanced prostate cancer and metastasis advanced prostate cancer, and the change of state in cellular immunity and humoral immunity before and after CSAP. Validate the clinical therapeutic effect of all kinds of prostate cancer, as well as the change of immune status before and after CSAP.

2. The main content of the study:

1. Included in the samples are patients in hospitals for CSAP. The sample capacity are planned to be 80. The main purpose of the study is to observe the overall survival rate , disease free survival rate, the progress time of the PSA biochemical recurrence as well as the disease progress time.
2. Measure the change of concentration in peripheral blood T lymphocyte subsets (CD3 + T, CD4 + T, CD8 + T, CD4 + / CD8 + T, NK cells) and regulatory T cells before and after cryoablation within 1 month, 3 months and 6 months.
3. Measure the change of concentration in peripheral blood IFN-1, IL-4, IFN-1/IL-4 ratio (Thl/Th2 ratio), and detect the secretion of CD4 + Th tumor-specific IFN-l and the activity of tumor-specific killer CD8 + CTL before and after cryoablation within 2 weeks and 1 month.
4. Before cryoablation, detect the expression and distribution of Follistatin-Like1 (FSTL-1), Besides, verify the connection between the number and activation ratio of tumor local dendritic cells (DC) and the FSTL-1, evaluating the cryoablation effect on the immune response.


Eligibility Criteria:
Inclusion Criteria:

* patients diagnosed with prostate cancer by pathology
* the age of patients should be from 40 to 80 years old
* do not receive other treatments like radical prostatectomy, radiotherapy, etc

Exclusion Criteria:

* can not receive surgery because of bad performance status
* abnormal coagulation function
* receive other treatment before CSAP
* do not want to achieve CSAP because of any reasons